Search results
Added:
3 years ago
A not inconsequential number of therapeutic agents or chemical substances can increase blood pressure (BP). The degree to which BP increases determines whether a specific definitional threshold has been crossed, at which time the patient is designated as having become hypertensive. Drugs that cause hypertension do so by either causing vasoconstriction, increasing extracellular fluid (ECF) volume,…
View more
Added:
3 years ago
The lower level to which blood pressure should be taken and how soon treatment should be started are key considerations where aging and cardiovascular mortality risks are concerned. It has long been taught that blood pressure should be allowed to rise to a level deemed pre-hypertensive or hypertensive before non-pharmacological and pharmacological therapy is embarked upon. Is this really the…
View more
Added:
3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease with limited treatment options. Although some patients do well with calcium channel blockers, most ultimately need more advanced therapy, such as prostanoids. Recently, a new class of therapeutic agents has been developed to treat these patients: the endothelin receptor antagonists (ERAs). Although they are not…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease with limited treatment options. Although some patients do well with calcium channel blockers, most ultimately need more advanced therapy, such as prostanoids. Recently, a new class of therapeutic agents has been developed to treat these patients: the endothelin receptor antagonists (ERAs). Although they are not…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a rare but life-threatening condition that has traditionally required treatment with continuous intravenous epoprostenol via an indwelling central catheter.1–3 Such therapy improves outcome, but is fraught with side effects, expense, and risk of catheter-related complications. Therapy of PAH has evolved tremendously in recent years, reflecting the…
View more
Added:
3 years ago
Added:
3 years ago
Epidemiology
Hypertension is both more common and more destructive in African-Americans than in other ethnic groups. According to the 2005–2006 National Health and Nutrition Examination Survey (NHANES) data, the current prevalence of hypertension in African-Americans is 39.1%, which is well above non-Hispanic whites at 28.5%. While awareness and treatment rates are similar between African…
View more
Added:
3 years ago
Hypertension (HT) remains the most common preventable risk factor for cardiovascular (CV) morbidity and mortality. There are exciting new data about epidemiology, brachial blood pressure (BP), ambulatory blood pressure monitoring (ABPM) and pre-hypertension from large clinical trials.
Increasing Burden of Hypertension Worldwide
The incidence of HT is rising worldwide due to common environmental…
View more
Added:
3 years ago
Hypertension is a major cause of morbidity and mortality worldwide.1–3 In the US, around 25% of the adult population has a blood pressure (BP) of ≥140/90mmHg, which is the defined cut-off value for hypertension.3 Although there are many effective pharmacotherapies available, many patients are not adequately controlled on their current antihypertensive regimens. The National Health and Nutrition…
View more
